Kaken Pharmaceutical Co Ltd
TSE:4521
Kaken Pharmaceutical Co Ltd
Total Equity
Kaken Pharmaceutical Co Ltd
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
K
|
Kaken Pharmaceutical Co Ltd
TSE:4521
|
Total Equity
¥145.8B
|
CAGR 3-Years
1%
|
CAGR 5-Years
2%
|
CAGR 10-Years
5%
|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Total Equity
¥7.6T
|
CAGR 3-Years
7%
|
CAGR 5-Years
11%
|
CAGR 10-Years
14%
|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Total Equity
¥1.7T
|
CAGR 3-Years
7%
|
CAGR 5-Years
6%
|
CAGR 10-Years
3%
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Total Equity
¥3T
|
CAGR 3-Years
11%
|
CAGR 5-Years
10%
|
CAGR 10-Years
6%
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Total Equity
¥2T
|
CAGR 3-Years
12%
|
CAGR 5-Years
15%
|
CAGR 10-Years
12%
|
|
|
Astellas Pharma Inc
TSE:4503
|
Total Equity
¥1.8T
|
CAGR 3-Years
4%
|
CAGR 5-Years
5%
|
CAGR 10-Years
3%
|
|
Kaken Pharmaceutical Co Ltd
Glance View
Founded in 1948, Kaken Pharmaceutical Co., Ltd. is a prominent player in Japan's pharmaceutical landscape, seamlessly blending tradition with innovation. The company's journey began amidst post-war economic rebuilding, initially catering to the nation's healthcare needs with basic medicines. Over the years, it has carved out a niche for itself, specializing in the development, manufacturing, and commercialization of a wide range of pharmaceutical products. Kaken's focus areas include dermatology, orthopedics, and surgery, with a strong emphasis on treatments for fungal infections and inflammation management. This specialization has propelled the company into a position of leadership, especially in the dermatology market, where its expertise in topical formulations excels. Kaken Pharmaceutical monetizes its ventures primarily through the sale of prescription and over-the-counter drugs, leveraging a robust distribution network that extends its reach across Japan and international markets. The company continually reinvests in research and development to sustain its competitive edge, regularly introducing innovative therapies that address unmet medical needs. While pharmaceuticals remain its core revenue stream, Kaken also generates income from its chemical businesses, which include agrochemicals and animal health products, further diversifying its portfolio. By maintaining a balanced blend of traditional pharmaceutical sales and chemical product lines, Kaken ensures steady financial footing while advancing health solutions for a global audience.
See Also
What is Kaken Pharmaceutical Co Ltd's Total Equity?
Total Equity
145.8B
JPY
Based on the financial report for Dec 31, 2025, Kaken Pharmaceutical Co Ltd's Total Equity amounts to 145.8B JPY.
What is Kaken Pharmaceutical Co Ltd's Total Equity growth rate?
Total Equity CAGR 10Y
5%
Over the last year, the Total Equity growth was -6%. The average annual Total Equity growth rates for Kaken Pharmaceutical Co Ltd have been 1% over the past three years , 2% over the past five years , and 5% over the past ten years .